Neutral lipid storage disease with fatty liver and cholestasis.
about
Mammalian patatin domain containing proteins: a family with diverse lipolytic activities involved in multiple biological functionsPhospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic interventionIdentification of mouse Prp19p as a lipid droplet-associated protein and its possible involvement in the biogenesis of lipid dropletsNeutral Lipid Storage Diseases: clinical/genetic features and natural history in a large cohort of Italian patients.CGI-58/ABHD5 is a coenzyme A-dependent lysophosphatidic acid acyltransferaseComparative gene identification 58/α/β hydrolase domain 5 lacks lysophosphatidic acid acyltransferase activityLipid droplets: size matters.CGI-58 knockdown in mice causes hepatic steatosis but prevents diet-induced obesity and glucose intolerance.Clinical and genetic characterization of Chanarin-Dorfman syndrome patients: first report of large deletions in the ABHD5 gene.Lipolysis - a highly regulated multi-enzyme complex mediates the catabolism of cellular fat stores.Not just fat: the structure and function of the lipid droplet.State of the art in muscle lipid diseases.Loss of abhd5 promotes colorectal tumor development and progression by inducing aerobic glycolysis and epithelial-mesenchymal transitionCGI-58/ABHD5 is phosphorylated on Ser239 by protein kinase A: control of subcellular localizationIntestinal Cgi-58 deficiency reduces postprandial lipid absorption.Adipose-selective overexpression of ABHD5/CGI-58 does not increase lipolysis or protect against diet-induced obesity.Muscle-specific deletion of comparative gene identification-58 (CGI-58) causes muscle steatosis but improves insulin sensitivity in male mice.ATGL-mediated fat catabolism regulates cardiac mitochondrial function via PPAR-α and PGC-1.Effects of rosiglitazone and high fat diet on lipase/esterase expression in adipose tissueAdipose triglyceride lipase acts on neutrophil lipid droplets to regulate substrate availability for lipid mediator synthesis.Distinct roles for alpha-beta hydrolase domain 5 (ABHD5/CGI-58) and adipose triglyceride lipase (ATGL/PNPLA2) in lipid metabolism and signaling.Distinct mechanisms regulate ATGL-mediated adipocyte lipolysis by lipid droplet coat proteinsiPS cell modeling of cardiometabolic diseasesMammalian alpha beta hydrolase domain (ABHD) proteins: Lipid metabolizing enzymes at the interface of cell signaling and energy metabolism.Biochemistry and pathophysiology of intravascular and intracellular lipolysis.Cardiac-specific overexpression of perilipin 5 provokes severe cardiac steatosis via the formation of a lipolytic barrier.Deficiency of liver Comparative Gene Identification-58 causes steatohepatitis and fibrosis in mice.Neutral lipid storage disease: genetic disorders caused by mutations in adipose triglyceride lipase/PNPLA2 or CGI-58/ABHD5.Fat in the skin: Triacylglycerol metabolism in keratinocytes and its role in the development of neutral lipid storage disease.Inborn errors of cytoplasmic triglyceride metabolism.Growth retardation, impaired triacylglycerol catabolism, hepatic steatosis, and lethal skin barrier defect in mice lacking comparative gene identification-58 (CGI-58).CGI-58 facilitates the mobilization of cytoplasmic triglyceride for lipoprotein secretion in hepatoma cells.ABHD5/CGI-58 facilitates the assembly and secretion of apolipoprotein B lipoproteins by McA RH7777 rat hepatoma cells.Molecular characterization of human ABHD2 as TAG lipase and ester hydrolase.Critical roles for α/β hydrolase domain 5 (ABHD5)/comparative gene identification-58 (CGI-58) at the lipid droplet interface and beyond.Renal involvement as a rare complication of Dorfman-Chanarin syndrome: a case report.
P2860
Q24653003-F6630C23-8981-4695-BB7F-5171E89BD930Q26997377-A23870E5-068F-4EE8-9101-E8D5E7A92CB0Q28592348-F23C66CD-C703-4E7A-9F59-8E71CFB97254Q33667982-CEC99BD1-2963-4AFC-9500-57FBA5D3A554Q33741180-64A4382E-7AF1-4A55-9876-A601B17D5A5EQ33945126-38F80966-3D94-4B4C-A8A5-21DA420D4536Q34028156-54B67C71-B115-458A-9D11-16BEFD4814EFQ34188075-2447D66B-2CBF-4E67-9A5A-85FAB88D56F8Q34482020-543E2357-014C-4AAB-8562-AD1CC9328DBCQ34543395-E6BA1FC3-F81E-4D07-849A-C68BB62ECF16Q34578014-72418EA1-B09C-43DC-BA08-9B3E3D9D287FQ34580810-9018906C-A6DF-4CA5-BD16-9CC6247B1BFEQ34717352-8A7EC5EC-84A4-46DA-831D-7A358A3ACFCBQ34757325-54C58D6E-D8CC-4127-A14C-220D2B0859E7Q35117538-1F6C5C88-77FC-43A8-A91C-50B9A28FF81CQ35380219-7C3B74AF-4CD5-4F52-9236-EDD639037A63Q35436264-09E84209-42AF-4E2D-8B57-4CAC0271A04EQ35630386-BE8F68DE-3844-40D4-BE99-200ACBB657B6Q35914800-8F4E275F-B277-4149-AA59-C5CC112ECAC9Q36125641-9208FA32-08DE-4314-8D95-9A33EA8098B1Q36382868-323ED8A6-5EB6-4DCE-8D54-14A01219FCA0Q36533395-6DED04A3-9A10-4ED7-98D7-D2EF40B41F58Q36539750-84770C06-B764-4028-85DC-BF0279A8C24FQ36612260-F70BCE2D-A593-4209-917C-98A85FF94803Q36708030-7E285859-8A55-4A8F-8B5A-3CB76FC311E0Q36709594-235906F1-EFE9-4AF7-BBF7-3E5392EBF71DQ37002642-DAF51378-35D7-45E3-9F74-85F4B3F8449FQ37463574-2EF8E039-FFB0-4703-AC38-515299A7B1BAQ37892924-FE6F4A85-A3A5-409C-B941-9AB51C484ED0Q38258625-4AB32A7B-5888-48F1-B875-DA8997633B6DQ39762596-B4B731FF-70D4-4731-B4BC-09F6D65CCD46Q40100342-E26998D0-C7BB-4F8B-B832-FC83549058E7Q41397987-355748B2-7E99-4CF3-A9E9-AD38165ACBC6Q42418890-1A2892E0-1A05-465C-9580-8385943994E9Q47925533-8077B545-8532-4393-A029-D14AEA9F512CQ51953591-93AA414C-F61F-4F93-B087-ED51C9AAEA64
P2860
Neutral lipid storage disease with fatty liver and cholestasis.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Neutral lipid storage disease with fatty liver and cholestasis.
@en
type
label
Neutral lipid storage disease with fatty liver and cholestasis.
@en
prefLabel
Neutral lipid storage disease with fatty liver and cholestasis.
@en
P2093
P1476
Neutral lipid storage disease with fatty liver and cholestasis.
@en
P2093
P304
P356
10.1097/00005176-199711000-00011
P407
P577
1997-11-01T00:00:00Z